
Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for hypoparathyroidism now in Phase 1 testing.
Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for hypoparathyroidism now in Phase 1 testing.
© 2023 LBNN - All rights reserved.